Medtronic, Inc. announced it has received U.S. Food and Drug Administration (FDA) approval for the MiniMed Paradigm® REAL-Time Revel™ System, an integrated diabetes management system which combines insulin pump therapy, continuous glucose monitoring (CGM) and diabetes therapy management software. The system incorporates new innovative CGM features including predictive alerts that can give early warning to people with diabetes so they can take action to prevent dangerous high or low glucose events.
This new system is another step towards the development of an Artificial Pancreas.
I love you guys at Medtronic…… No seriously…You are doing great work!